Effects of X-ray irradiation on the overexpression of HER-2/Erb-B2 on breast cancer cell lines

Journal of Experimental and Clinical Cancer Research

Volumn 23, Issue 4, 2004, Pages 675-680

  Juranić, Zorica D ^a   Borojevic N ^a   Jovanovic D ^a   Stanojevic Bakic N ^a   Zizak Z ^a   Neskovic Konstantinovic, Z ^a   Saric M ^a   Stanojkovic T ^a   Raonic T ^a   Milosevic D ^a  

^a INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

Author keywords

Cytotoxicity; HER 2 receptors; Irradiation; MDA MB 361 and MDA MB 453 breast carcinoma cell lines

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER PATIENT; CELL SURVIVAL; CONTROLLED STUDY; CYTOLOGY; CYTOTOXICITY; DIAGNOSTIC VALUE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; PRIORITY JOURNAL; X IRRADIATION;

ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; COLORING AGENTS; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM METASTASIS; RECEPTOR, ERBB-2; TETRAZOLIUM SALTS; THIAZOLES; TIME FACTORS; TRYPAN BLUE; X-RAYS;

EID: 19944432208     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Sikov W.M.: Locally advanced breast cancer. Curr. Treat. Options Oncol. 1: 228-238, 2000.
2. Carter P., Presta L., Gorman C.M., Ridgway J.B., Henner D., Wong W.L., Rowland A.M., Kotts C., Carver M.E., Shepard H.M.: Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. U.S.A. 89: 4285-4289, 1992.
3. Vogel C.L., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenbacher L., Slamon D.J., Murphy M., Novotny W.F., Burchmore M., Shak S., Stewart S.J., Press M.: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20: 719-726, 2002.
4. Baselga J., Albanell J., Molina M.A., Arribas J.: Mechanism of action of trastuzumab and scientific update. Semin. Oncol. 28(Suppl 16): 4-11, 2001.
5. Devine D. V.: The regulation of complement on cell surfaces. Transfus. Med. Rev. 5: 123-131, 1991.
6. Lewis G.D., Figari I., Fendly B., Wong W.L., Carter P., Gorman C., Shepard H.M.: Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol. Immunother. 37: 255-263, 1993.
7. Sliwkowski M.X., Lofgren J.A., Lewis G.D., Hotaling T.E., Fendly B.M., Fox J.A.: Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin. Oncol. 26(Suppl 12): 60-70, 1999.
8. Juranić Z., Stanojević-Bakić N., Nesković-Konstantinović Z., Žizak Ž., Stanojković T., Radulović S., Milosević D.: The importance of antibody dependent cell-mediated cytotoxicity (ADCC) for breast cancer response to trastuzumab (Herceptin®). Archives of Oncology 10: 162-163, 2002.
9. Rhodes A., Jasani B., Anderson E., Dodson A.R., Balaton A.J.: Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries. Am. J. Clin. Pathol. 118: 408-417, 2002.
10. Boyd M.R., Paull K.D.: Some practical considerations and applications of the National Cancer Institute in vitro anti-cancer drug discovery screen. Drug Development Research 34: 91-109, 1995.
11. Ohno M., Abe T.: Rapid colorimetric assay for the quantification of leukemia inhibitory factor (LIF) and interleukin-6 (IL-6). J. Immunol. Methods 145: 199-203, 1991.
12. Jarvinen T.A., Tanner M., Rantanen V., Barlund M., Borg A., Grenman S., Isola J.: Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am. J. Pathol. 156: 839-847, 2000.
13. Fukutomi T., Yamamoto H., Nanasawa T., Tsukiyama I., Ogino H., Itabashi M., Hirota T.: (Histological and biological evaluation of preoperative radiotherapy on T1N0 breast carcinoma). Nippon Geka Gakkai Zasshi; 93: 183-188, 1992.
14. Uno M., Otsuki T., Kurebayashi J., Sakaguchi H., Isozaki Y., Ueki A., Yata K., Fujii T, Hiratsuka J., Akisada T., Harada T, Imajo Y: Anti-HER2-antibody enhances irradiation-induced growth inhibition in head and neck carcinoma. Int. J. Cancer 94: 474-479, 2001.